瑞舒伐他汀钙对高血压患者颈动脉粥样硬化的影响

Effects of rosuvastatin calcium therapy on carotid atherosclerosis in patients with essential hypertension

目的观察抗高血压药物联合瑞舒伐他汀钙对原发性高血压患者的血脂指标、颈动脉内膜-中层厚度(CIMT)和颈动脉斑块总积分的影响。方法收集2015年1月至2016年1月在西安交通大学医院诊治的58例原发性高血压患者,根据用药不同分为2组,其中对照组28例,采用单纯抗高血压药物治疗;观察组30例,采用抗高血压药物联合瑞舒伐他汀钙治疗。比较2组患者在治疗前和治疗后12、24、40周的血脂指标,CIMT,颈动脉斑块总积分。结果与对照组比较,观察组患者在治疗12、24、40周后,胆固醇(CHO),低密度脂蛋白胆固醇(LDL-C),载脂蛋白B(Apo B)均明显降低,差异有统计学意义(P<0.05);在治疗24、40周后,观察组患者的CIMT和颈动脉斑块总积分均明显降低,差异有统计学意义(P<0.05)。与治疗12周比较,在治疗40周后,观察组患者的CHO、LDL-C、Apo B均明显降低,差异有统计学意义(P<0.05)。与治疗12周比较,在治疗24、40周后,观察组患者的CIMT和颈动脉斑块总积分均明显降低,差异有统计学意义(P<0.05)。与24周比较,在治疗40周后,观察组患者的CIMT和颈动脉斑块总积分均明显降低,差异有统计学意义(P<0.05)。结论长期抗高血压药物联合瑞舒伐他汀钙治疗原发性高血压,可以明显降低血脂指标和CIMT,改善颈动脉斑块。

Objective To observe the effect of blood lipid index, carotid intima-media thickness（CIMT） and total carotid plaque score of patients with essential hypertension through the therapy of antihypertensive drug combined rosuvastatin calcium. Methods From January 2015 to January 2016, 58 patients with essential hypertension were selected and according different medicines all patients were divided into two groups. 28 cases of only treatment with antihypertensive drugs were selected as control group; 30 cases combining rosuvastatin calcium with antihypertensive drugs were selected as observation group. The blood lipid indexes, CIMT and total carotid plaque score of two groups were compared before treatment, at 12, 24, 40 weeks after treatment. Results After lipid-regulating therapy for 12, 24, 40 weeks in observation group, the total cholesterol（CHO）, low density lipoprotein cholesterol（LDL-C）, apolipoprotein B（Apo B） were lower than those in control group, the differences were statistically significant（P〈0.05）. After lipid-regulating therapy for 24 weeks and 40 weeks, CIMT and the total carotid plaques score were lower than those in control group, the differences were statistically significant（P〈0.05）. After lipid-regulating therapy for 40 weeks in observation group, CHO, LDL-C and Apo B were lower than those after therapy for 12 weeks, the differences were statistically significant（P〈0.05）. After lipid-regulating therapy for 40 weeks in observation group, CIMT and the total carotid plaques score were lower than those after 24 weeks, the differences were statistically significant（P〈0.05）. Conclusions The long-term combination of rosuvastatin calcium with antihypertensive drug in the treatment of patients with essential hypertension can significantly reduce blood lipid index, CIMT and improve carotid plaque.